ESMO: Metastatic Breast Cancer
<ѻý class="page-description">European Society for Medical Oncologyѻý>More in ESMO: Metastatic Breast Cancer
Data have narrowed first- and second-line choices, but decisions must be tailored to the patient
Nov 21, 2023
Antibody-drug conjugates in particular may present clinicians with less familiar side effects
Nov 15, 2023
A three-question quiz on HER2-low disease, brain metastases, and progression on CDK4/6 inhibitors
Sep 30, 2022
Rapidly changing landscape has brought new targeted agents and made staying up-to-date vital
Sep 30, 2022